3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
8
Active not recruiting
3
Terminated
2
Not yet recruiting
2
Recruiting
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
25
Carcinoma, Intraductal, Noninfiltrating
3
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HR Positive HER2 Negative Advanced Breast Cancer
1
HER2 Negative Breast Cancer
1
Fallopian Tube Neoplasms
1
Endometrial Stromal Tumors
1
ER+ Breast Cancer
1
Anatomic Stage III Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
38
Blood Specimen Collection
38
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
17
Exercise
17
Carboplatin
17
Nivolumab
15
atezolizumab
14
Paclitaxel
14
Cisplatin
14
Drug Therapy
13
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
11
Trastuzumab
10
Pemetrexed
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Anastrozole
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled